When this peptide was administered before disease onset, male BXSB.Yaa mice that received RPA treatment (RPA) were protected from splenomegaly (Fig 7A) and lymphadenopathy (Appendix Fig S3B), with a reduced serum secretion of IgG and ANA compared with male BXSB. This evidence concerns the gene BTG3 and Splenomegaly.